Opinion|Videos|May 7, 2025
Adjunctive Treatments and Apomorphine for Treatment of Parkinson Disease
Panelists discuss how adjunctive therapies play a crucial role in managing Parkinson disease symptoms, with a particular focus on apomorphine’s unique position in the treatment landscape due to its distinct dopamine receptor binding profile compared with other dopaminergic agents.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Adjunctive Therapy and Apomorphine’s Role
Role of Adjunctive Therapy:
- Extends levodopa efficacy by addressing pharmacokinetic/pharmacodynamic limitations
- Allows for levodopa dose reduction while maintaining symptom control
- Targets specific symptom patterns (eg, morning akinesia, wearing off)
- Addresses treatment gaps not fully managed by levodopa
Apomorphine’s Position in Treatment Landscape:
- Potent, nonergoline dopamine agonist
- Rapid-onset rescue medication for acute off episodes
- Continuous infusion option for patients with frequent off periods
- Bypass gastrointestinal absorption issues via subcutaneous administration
- Often considered before surgical interventions such as deep brain stimulation
Dopamine Receptor Binding Profile:
- High affinity for D2 receptors (similar to other dopamine agonists)
- Additional significant D1 receptor activity (more similar to levodopa)
- Some D3 and D4 receptor activity
- More balanced receptor profile than most oral dopamine agonists
- Rapid onset of action (10-20 minutes) compared with oral medications
Advertisement
Related to this article
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
2
New York Forum Tackles Unmet Needs in Multiple Sclerosis Care
3
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5